Market Research Logo

Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review

Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains crit

    ical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Synta Pharmaceuticals Corp. (Synta) is a pharmaceutical company that discovers, develops and commercializes novel pharmaceutical products for the treatment of cancer and other severe medical conditions. It has a unique chemical compound, an integrated discovery engine and a diverse pipeline of clinical and preclinical stage drug candidates. The company has a clinical-stage drug candidate (ganetespib) in cancer and a novel, proprietary small molecule cancer drug development program, the HDC program. Ganetespib is a novel, potent, small molecule inhibitor of Hsp90, a molecular chaperone required for the proper folding and activation of various cancer-promoting proteins. Synta is headquartered in Lexington, Massachusetts, the US.

Synta Pharmaceuticals Corp. Key Recent Developments

Nov 05, 2015: Synta Reports Third Quarter 2015 Financial Results
Sep 09, 2015: Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer
Aug 06, 2015: Synta Reports Second Quarter 2015 Financial Results
May 07, 2015: Synta Reports First Quarter 2015 Financial Results
Apr 27, 2015: Synta Announces Chen Schor Named President, Chief Executive Officer and Director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Synta Pharmaceuticals Corp. - Key Facts
Synta Pharmaceuticals Corp. - Key Employees
Synta Pharmaceuticals Corp. - Key Employee Biographies
Synta Pharmaceuticals Corp. - Major Products and Services
Synta Pharmaceuticals Corp. - Pharmaceutical Pipeline Products Data
Synta Pharmaceuticals Corp., Pipeline Products by Therapy Area
Synta Pharmaceuticals Corp., Pipeline Products by Development Phase
Synta Pharmaceuticals Corp. - History
Synta Pharmaceuticals Corp. - Company Statement
Synta Pharmaceuticals Corp. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Synta Pharmaceuticals Corp. - Business Description
Synta Pharmaceuticals Corp. - Corporate Strategy
Synta Pharmaceuticals Corp. - SWOT Analysis
SWOT Analysis - Overview
Synta Pharmaceuticals Corp. - Strengths
Strength - Research and Development Activities
Strength - Proprietary Technology Platform
Synta Pharmaceuticals Corp. - Weaknesses
Weakness - History of losses
Weakness - Product Discontinuations
Synta Pharmaceuticals Corp. - Opportunities
Opportunity - Pipeline of Cancer Products
Opportunity - Market Potential: Cancer
Opportunity - Merger Agreement with Madrigal
Synta Pharmaceuticals Corp. - Threats
Threat - Intense Competition
Threat - Reliance on Third Parties
Threat - Stringent Government Regulations
Synta Pharmaceuticals Corp. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Synta Pharmaceuticals Corp., Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 05, 2015: Synta Reports Third Quarter 2015 Financial Results
Sep 09, 2015: Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer
Aug 06, 2015: Synta Reports Second Quarter 2015 Financial Results
May 07, 2015: Synta Reports First Quarter 2015 Financial Results
Apr 27, 2015: Synta Announces Chen Schor Named President, Chief Executive Officer and Director
Mar 12, 2015: Synta Reports Fourth Quarter and Year-End 2014 Financial Results
Feb 05, 2015: Synta Outlines New Corporate Strategy
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Synta Pharmaceuticals Corp., Key Facts
Synta Pharmaceuticals Corp., Key Employees
Synta Pharmaceuticals Corp., Key Employee Biographies
Synta Pharmaceuticals Corp., Major Products and Services
Synta Pharmaceuticals Corp., Number of Pipeline Products by Therapy Area
Synta Pharmaceuticals Corp., Number of Pipeline Products by Development Stage
Synta Pharmaceuticals Corp., Pipeline Products By Therapy Area and Development Phase
Synta Pharmaceuticals Corp., History
Synta Pharmaceuticals Corp., Other Locations
Synta Pharmaceuticals Corp., Subsidiaries
Synta Pharmaceuticals Corp., Key Competitors
Synta Pharmaceuticals Corp., Ratios based on current share price
Synta Pharmaceuticals Corp., Annual Ratios
Synta Pharmaceuticals Corp., Interim Ratios
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Synta Pharmaceuticals Corp., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Synta Pharmaceuticals Corp., Pipeline Products by Therapy Area
Synta Pharmaceuticals Corp., Pipeline Products by Development Phase
Synta Pharmaceuticals Corp., Performance Chart (2011 - 2015)
Synta Pharmaceuticals Corp., Ratio Charts
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report